While automation is crucial for ensuring consistent, replicable experiments by eliminating human variability, it risks removing the "irregularity" that can lead to unexpected breakthroughs. This creates a new design challenge: engineering for human ingenuity alongside automated systems.
As AI and automation become central to drug discovery, the physical layout and infrastructure of a lab are no longer just a facility. They are a core competitive advantage, an "experiment upon themselves" that companies actively protect as valuable IP to prevent replication by rivals.
Traditional "flexible" lab design pre-engineers for every possible future scenario, which is expensive and rigid. A smarter approach is "adaptability": consciously designing pathways and leaving space for future technology without over-investing in systems that may quickly become obsolete.
The deep focus required by computational scientists clashes with the open-office model. Furthermore, the emerging behavior of researchers verbally interacting with AI models introduces new acoustic and privacy challenges, making traditional layouts unsuitable for the focused nature of modern R&D.
Companies wanting to keep sensitive research data on-site are discovering a major infrastructure challenge. Even a small, local data center can double a lab facility's total power consumption, a critical and costly factor that must be planned for well in advance of securing space.